Novo Nordisk A/S logo
Novo Nordisk A/S NVO
$ 50.0 -0.58%

Annual report 2024
added 12-06-2025

report update icon

Novo Nordisk A/S Gross Profit 2011-2025 | NVO

Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.

Calculation formula:
Gross Profit = Revenue – Cost of Goods Sold (COGS)

Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
  • Raw materials and supplies
  • Wages of production personnel
  • Depreciation of equipment
  • Transportation and warehousing costs (if directly related to production)
Importance for business:
  • Assessing core business profitability
    If gross profit is declining, it may indicate rising production costs or falling sales.
  • Financial planning
    Gross profit is the basis for calculating other key metrics, such as operating and net profit.
  • Benchmarking against competitors
    Gross profit analysis helps compare the efficiency of different companies within the same industry.
  • Insights into pricing effectiveness
    If gross profit is low, the company may be pricing too low or failing to control costs effectively.
Reasons for a decline in gross profit:
  • Increase in raw material and supply costs
  • Rising production expenses
  • Price reductions due to competition
  • Decrease in sales volume
  • Currency exchange rate fluctuations (for imports/exports)

Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.

Annual Gross Profit Novo Nordisk A/S

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
246 B 196 B 149 B 117 B 106 B 102 B 94.2 B 94.1 B 94.6 B 91.7 B 74.2 B 69.4 B 64.6 B 53.8 B

All numbers in DKK currency

Indicator range from annual reports

Maximum Minimum Average
246 B 53.8 B 111 B

Gross Profit of other stocks in the Biotechnology industry

Issuer Gross Profit Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
180 M - 2.43 % $ 254 M germanyGermany
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
5.52 B - - $ 40.3 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
319 M $ 220.27 4.81 % $ 5 B danmarkDanmark
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
2.03 M $ 0.28 -2.28 % $ 609 M israelIsrael
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
177 K $ 3.3 -3.51 % $ 7.94 B australiaAustralia
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
12.1 - -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-428 K - -18.52 % $ 27.3 M britainBritain
Aptorum Group Limited Aptorum Group Limited
APM
-104 K $ 1.29 -3.01 % $ 7.03 M chinaChina
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
774 M - - - russiaRussia
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
-40.6 M $ 4.75 1.61 % $ 788 M canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
172 K $ 3.26 -3.12 % $ 252 M usaUSA
Acasti Pharma Acasti Pharma
ACST
-32.3 K - 4.01 % $ 150 M canadaCanada
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
1.12 M - -15.15 % $ 60.3 M britainBritain
Albireo Pharma Albireo Pharma
ALBO
39.2 M - -0.23 % $ 916 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-523 K - -11.43 % $ 502 K usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
374 M $ 25.27 -2.43 % $ 1.22 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
103 M $ 9.57 0.84 % $ 140 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
319 K - -6.81 % $ 3.04 B usaUSA
Athersys Athersys
ATHX
1.44 M - 3.77 % $ 22.4 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
1.27 M - 2.71 % $ 14 M usaUSA
Axon Enterprise Axon Enterprise
AXON
1.24 B $ 566.18 -2.56 % $ 42.9 B usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
90 K - - $ 7.46 M israelIsrael
Aytu BioScience Aytu BioScience
AYTU
45.8 M $ 2.34 2.59 % $ 14.7 M usaUSA
AstraZeneca PLC AstraZeneca PLC
AZN
43.9 B $ 89.78 -0.57 % $ 96.9 B britainBritain
Acorda Therapeutics Acorda Therapeutics
ACOR
119 M - -24.86 % $ 820 K usaUSA
Brickell Biotech Brickell Biotech
BBI
1.82 K - -5.38 % $ 6.06 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
3.22 B - 0.49 % $ 251 B cayman-islandsCayman-islands
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
371 M $ 11.54 0.87 % $ 746 M usaUSA
Biogen Biogen
BIIB
12.4 B $ 174.42 1.11 % $ 25.4 B usaUSA
Abeona Therapeutics Abeona Therapeutics
ABEO
925 K $ 5.36 -2.99 % $ 115 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
15.8 M $ 10.85 -0.14 % $ 1.41 B usaUSA
ADiTx Therapeutics ADiTx Therapeutics
ADTX
-493 K $ 2.3 -3.0 % $ 30.3 K usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
500 - -9.72 % $ 5.89 M usaUSA
Berkeley Lights Berkeley Lights
BLI
53.8 M - -7.31 % $ 87 M usaUSA
Advaxis Advaxis
ADXS
90 K - -9.65 % $ 45.9 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
325 M - - - russiaRussia
Фармсинтез Фармсинтез
LIFE
160 M - - - russiaRussia
BioLineRx Ltd. BioLineRx Ltd.
BLRX
19.7 M $ 3.17 -1.86 % $ 908 M israelIsrael
bluebird bio bluebird bio
BLUE
-4.03 M - - $ 546 M usaUSA